---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-24-000086"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:19:24.481966+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biohaven reports Q3 net loss $160.3M; troriluzole SCA trial positive, NDA submission planned Q4 2024

## Summary
- Net loss $160.3M ($1.70/sh) vs $102.6M loss ($1.50/sh) in Q3 2023; non-GAAP adj. net loss $164.1M ($1.74/sh).
- Cash position $642M as of Oct 2, 2024, including $269.9M net from Oct 2024 public offering of 6.05M shares at $47.50.
- Troriluzole met primary endpoint in pivotal SCA trial; NDA submission to FDA on track for Q4 2024.
- Initiated Phase 2 trial of BHV-2100 (TRPM3 antagonist) in acute migraine; expects Phase 3 SMA topline data in Q4 2024.
- R&D expenses rose to $157.6M from $95.5M YoY due to advancing late-stage trials.

## SEC filing metadata
- accession: 0001935979-24-000086
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/0001935979-24-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/bhvn-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-24-000086
- JSON: https://secwatch.observer/filing/0001935979-24-000086.json
- Plain text: https://secwatch.observer/filing/0001935979-24-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.